Dr. David Briscoe Joins aTyr Pharma, Inc as Scientific Advisor
August 06, 2019 at 05:30 pm IST
Share
aTyr Pharma, Inc. announced the appointment of David Briscoe, MB, ChB, Director of the Transplant Research Program and Fellowship Program and Professor of Pediatrics at Harvard Medical School as scientific advisor to the company. Dr. David Briscoe is a Professor of Pediatrics at Harvard Medical School and the Casey Lee Ball Chair in Transplantation at Boston Children's Hospital. He trained in pediatrics, nephrology and transplantation immunology, and directs a research program focused on the understanding of chronic allograft rejection with a goal to enhance long-term outcomes following solid organ transplantation. Dr. Briscoe serves on National Institutes of Health (NIH) study sections and is a regular participant providing transplant expertise on special grant review committees.
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).